PA8589101A1 - Lamina revestida de adhesivo para administracion dermica de un inhibidor selectivo de ciclooxigenasa-2 - Google Patents
Lamina revestida de adhesivo para administracion dermica de un inhibidor selectivo de ciclooxigenasa-2Info
- Publication number
- PA8589101A1 PA8589101A1 PA20038589101A PA8589101A PA8589101A1 PA 8589101 A1 PA8589101 A1 PA 8589101A1 PA 20038589101 A PA20038589101 A PA 20038589101A PA 8589101 A PA8589101 A PA 8589101A PA 8589101 A1 PA8589101 A1 PA 8589101A1
- Authority
- PA
- Panama
- Prior art keywords
- subject
- composition
- active agent
- understands
- skin area
- Prior art date
Links
- 239000000853 adhesive Substances 0.000 title abstract 3
- 230000001070 adhesive effect Effects 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000010985 leather Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 abstract 1
- 229960002004 valdecoxib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
UNA COMPOSICION FARMACEUTICA PARA LA APLICACION SOBRE UN AREA DE PIEL DE UN SUJETO PARA TRATAMIENTO LOCAL Y/O SITEMICO DE UN TRASTORNO MEDIADO POR COX-2 COMPRENDE UNA LAMINA DE SOPORTE QUE SE PUEDE ADAPTAR FLEXIBLEMENTE AL AREA DE PIEL, TENIENDO LA LAMINA DE SOPORTE SUPERFICIES OPUESTAS QUE SON RESPECTIVAMENTE DISTALES Y PROXIMALES A LA PIEL CUANDO SE APLICA; Y UN REVESTIMIENTO SOBRE LA SUPERFICIE PROXIMAL DE LA LAMINA DE SOPORTE QUE COMPRENDE (a) UN ADHESIVO Y (b) UN AGENTE ACTIVO QUE COMPRENDE VALDECOXIB O UNO DE SUS PROFARMACOS O UNA DE SUS SALES, ESTANDO EL AGENTE ACTIVO EN UNA CANTIDAD TOTAL TERAPEUTICAMENTE EFECTIVA Y DISPERSO EN UNA MATRIZ QUE COMPRENDE DE NADA A MENOS DE UNA CANTIDAD EFECTIVA QUE SOLUBILIZA UN AGENTE ACTIVO EN TOTAL DE UNO O MAS DISOLVENTES DIFERENTES DEL ADHESIVO. UN PROCEDIMIENTO DE TRATAMIENTO LOCAL DE UN SITIO DE DOLOR Y/O INFLAMACION EN UN SUJETO COMPRENDE LA APLICACION DE LA COMPOSICION SOBRE LA SUPERFICIE DE PIEL DEL SUJETO, PREFERIBLEMENTE EN UNA LOCALIZACION SUPERPUESTA O ADYACENTE AL SITIO DE DOLOR Y/O INFLAMACION, Y DEJANDO LA COMPOSICION EN EL LUGAR DURANTE UN PERIODO DE TIEMPO EFECTIVO PARA PERMITIR LA LIBERACION DE UNA CANTIDAD LOCALMENTE TERAPEUTICA DEL AGENTE ACTIVO. UN PROCEDIMIENTO DE TRATAMIENTO SISTEMICO DE UN SUJETO QUE TIENE UN TRASTORNO MEDIADO POR COX-2 COMPRENDE APLICAR LA COMPOSICION SOBRE UNA SUPERFIECIE DE PIEL DEL SUJETO, Y DEJAR LA COMPOSICION EN EL LUGAR DURANTE UN PERIODO DE TIEMPO EFCTIVO PARA PERMITIR LA LIBERACION TRANSDERMICA DE UNA CANTIDAD TERAPEUTICA DEL AGENTE ACTIVO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42820802P | 2002-11-21 | 2002-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8589101A1 true PA8589101A1 (es) | 2005-02-04 |
Family
ID=32393363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20038589101A PA8589101A1 (es) | 2002-11-21 | 2003-11-19 | Lamina revestida de adhesivo para administracion dermica de un inhibidor selectivo de ciclooxigenasa-2 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040127531A1 (es) |
| EP (1) | EP1565169A1 (es) |
| JP (1) | JP2006509761A (es) |
| AR (1) | AR042104A1 (es) |
| AU (1) | AU2003287732A1 (es) |
| BR (1) | BR0316275A (es) |
| CA (1) | CA2501287A1 (es) |
| GT (1) | GT200300247A (es) |
| MX (1) | MXPA05005510A (es) |
| NL (1) | NL1024816C2 (es) |
| PA (1) | PA8589101A1 (es) |
| PE (1) | PE20040548A1 (es) |
| TW (1) | TW200427471A (es) |
| UY (1) | UY28087A1 (es) |
| WO (1) | WO2004047815A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4283507B2 (ja) * | 2002-08-02 | 2009-06-24 | 久光製薬株式会社 | 経皮投与用貼付剤 |
| CA2551523A1 (en) * | 2003-12-24 | 2005-07-21 | Pharmacia Corporation | Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever |
| US7666914B2 (en) * | 2004-06-03 | 2010-02-23 | Richlin David M | Topical preparation and method for transdermal delivery and localization of therapeutic agents |
| US20070258935A1 (en) * | 2006-05-08 | 2007-11-08 | Mcentire Edward Enns | Water dispersible films for delivery of active agents to the epidermis |
| US20070259029A1 (en) * | 2006-05-08 | 2007-11-08 | Mcentire Edward Enns | Water-dispersible patch containing an active agent for dermal delivery |
| US20080057090A1 (en) * | 2006-09-01 | 2008-03-06 | Mcentire Edward Enns | Wrinkle masking film composition for skin |
| US7879942B2 (en) * | 2006-10-05 | 2011-02-01 | Eastman Chemical Company | Switchable adhesive article for attachment to skin and method of using the same |
| US8445037B2 (en) * | 2008-10-28 | 2013-05-21 | A. M. Todd Company | Volatile distillate by-product of mint oil that promotes absorption and/or bioavailability of compounds of bio-medical and nutritional interest |
| US8563031B2 (en) * | 2010-05-27 | 2013-10-22 | Absize, Inc. | Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith |
| JP2012020991A (ja) * | 2010-06-16 | 2012-02-02 | Takasago Internatl Corp | 経皮吸収促進剤、及びこれを含有する皮膚外用製剤 |
| WO2014097422A1 (ja) * | 2012-12-19 | 2014-06-26 | ニチバン株式会社 | 顔面用貼付材 |
| US20160256407A1 (en) * | 2013-10-11 | 2016-09-08 | Xep, Inc. | Energy patch |
| KR20190005199A (ko) | 2016-05-05 | 2019-01-15 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| KR102845228B1 (ko) * | 2017-09-27 | 2025-08-14 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 투과를 가지는 약물학적 조성물 |
| KR102042456B1 (ko) * | 2018-03-22 | 2019-11-08 | 크리스탈지노믹스(주) | 경피흡수제제 |
| WO2023076281A1 (en) | 2021-10-25 | 2023-05-04 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK285353B6 (sk) * | 1996-04-12 | 2006-11-03 | G. D. Searle & Co. | Substituované benzénsulfónamidy ako proliečivá COX-2 inhibítorov, farmaceutická kompozícia a spôsobich prípravy a použitia |
| US5952000A (en) * | 1996-10-30 | 1999-09-14 | Theratech, Inc. | Fatty acid esters of lactic acid salts as permeation enhancers |
| AU2816700A (en) * | 1999-03-01 | 2000-09-21 | Amarin Technologies S.A. | Transdermal device comprising non-steroidal anti-inflammatory drugs incorporatedin acrylic adhesive polymer matrix |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| IN191512B (es) * | 2000-01-21 | 2003-12-06 | Panacea Biotech | |
| DE10032132A1 (de) * | 2000-07-01 | 2002-01-17 | Lohmann Therapie Syst Lts | Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung |
| KR20040033286A (ko) * | 2001-05-31 | 2004-04-21 | 파마시아 코포레이션 | 선택적인 사이클로옥시게나제-2 억제제 및 1가 알콜을포함하는 피부-침투성 조성물 |
| JP4283507B2 (ja) * | 2002-08-02 | 2009-06-24 | 久光製薬株式会社 | 経皮投与用貼付剤 |
-
2003
- 2003-10-28 US US10/695,025 patent/US20040127531A1/en not_active Abandoned
- 2003-11-12 WO PCT/US2003/036362 patent/WO2004047815A1/en not_active Ceased
- 2003-11-12 JP JP2004555449A patent/JP2006509761A/ja not_active Withdrawn
- 2003-11-12 AU AU2003287732A patent/AU2003287732A1/en not_active Abandoned
- 2003-11-12 CA CA002501287A patent/CA2501287A1/en not_active Abandoned
- 2003-11-12 EP EP03781939A patent/EP1565169A1/en not_active Withdrawn
- 2003-11-12 BR BR0316275-3A patent/BR0316275A/pt not_active IP Right Cessation
- 2003-11-12 MX MXPA05005510A patent/MXPA05005510A/es unknown
- 2003-11-19 NL NL1024816A patent/NL1024816C2/nl not_active IP Right Cessation
- 2003-11-19 PA PA20038589101A patent/PA8589101A1/es unknown
- 2003-11-20 AR ARP030104296A patent/AR042104A1/es unknown
- 2003-11-20 TW TW092132571A patent/TW200427471A/zh unknown
- 2003-11-20 GT GT200300247A patent/GT200300247A/es unknown
- 2003-11-20 PE PE2003001177A patent/PE20040548A1/es not_active Application Discontinuation
- 2003-11-21 UY UY28087A patent/UY28087A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NL1024816C2 (nl) | 2006-03-06 |
| PE20040548A1 (es) | 2004-08-28 |
| US20040127531A1 (en) | 2004-07-01 |
| EP1565169A1 (en) | 2005-08-24 |
| BR0316275A (pt) | 2005-10-04 |
| TW200427471A (en) | 2004-12-16 |
| AR042104A1 (es) | 2005-06-08 |
| JP2006509761A (ja) | 2006-03-23 |
| NL1024816A1 (nl) | 2004-05-26 |
| MXPA05005510A (es) | 2005-07-25 |
| UY28087A1 (es) | 2004-06-30 |
| AU2003287732A1 (en) | 2004-06-18 |
| CA2501287A1 (en) | 2004-06-10 |
| WO2004047815A1 (en) | 2004-06-10 |
| GT200300247A (es) | 2004-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8589101A1 (es) | Lamina revestida de adhesivo para administracion dermica de un inhibidor selectivo de ciclooxigenasa-2 | |
| ATE434458T1 (de) | Austragungsvorrichtungen für eine lokal begrenzte austragung eines pleurodesewirkstoffes | |
| AR046697A1 (es) | Metodo y sistema de administracion transdermica de agente asistido por frecuencia | |
| BRPI0415466A (pt) | método e sistema de pré-tratamento para intensificar a distribuição transdérmica de fármacos | |
| BR0112356A (pt) | Formulações farmacêuticas tópicas e métodos de tratamento | |
| NO20034684D0 (no) | Innretning for administrering av midler gjennom stratum corcum | |
| AR042815A1 (es) | Dispositivo de suministro de agente activo que tiene miembros compuestos | |
| FI962770A0 (fi) | Transdermaalinen laite, joka sisältää polyvinyylipyrrolidonia liukoisuutta parantavana aineena | |
| WO2004078122A3 (en) | Invisible patch for active agnet controlled delivery | |
| BR0306513A (pt) | tampão com medicamento | |
| CL2004000931A1 (es) | Pelicula consumible adaptada para adherirse y disolverse en la cavidad bucal que comprende un almidon modificado y un agente farmaceuticamente activo. | |
| BRPI0517501A (pt) | dispositivo médico apropriado para uso na administração de um componente ativo na ou através da pele | |
| BRPI0903464B8 (pt) | formulação aquosa de um agente terapêutico e método para criar um dispositivo de aplicação de fármacos | |
| PA8589001A1 (es) | Administracion dermica de un inhibidor de ciclooxigenasa-2 selectivo soluble en agua | |
| BRPI0415986A (pt) | método e aparelho para reduzir a incidência do uso de tabaco | |
| NO20061859L (no) | OROS Push Stick for kontrollert tilforsel av aktive midler | |
| AR048827A1 (es) | Aparato y metodo para la administracion transdermica de agentes basados en fentanil | |
| BR0316436A (pt) | Emplastro inibidor seletivo de ciclooxigenase-2 | |
| BRPI0415725A (pt) | formulação aspergìvel transdérmica, método para administrar um agente farmaceuticamente ativo e método para formar uma pelìcula farmaceuticamente ativa | |
| WO2002017928A3 (de) | Transdermales therapeutisches system zur abgabe von exemestan | |
| DOP2003000759A (es) | Lamina revestida de adhesivo para administracion dermica de un inhibidor selectivo de ciclooxigenasa-2 | |
| DOP2003000758A (es) | Administracion dermica de un inhibidor de ciclooxigenasa-2 selectivo soluble en agua | |
| AR054225A1 (es) | Aparato y metodo para suministro transdermico de agentes basados en epoyetina | |
| ES2179658T3 (es) | Uso de oxazolidinonas para la preparacion de un medicamento de suministro transdermico. | |
| DK0667774T3 (da) | Transdermalt, terapeutisk system til indgivelse af physostigmin genem huden og fremgangsmåde til dets fremstilling |